Chestnut Pollen Allergy: Dual Cross-Reactivity With Food and Latex Allergens

The chestnut-latex-banana syndrome is a cross-reactivity pattern driven by shared hevein domain proteins found in chestnut (Cas s 5), natural rubber latex (Hev b 11), banana (Mus a 2), avocado (Pers a 1), and kiwi. Hevein is a chitin-binding protein motif that triggers IgE cross-recognition among these structurally unrelated allergen sources. A patient sensitized to any one of these can develop reactions to the others. The clinical significance is substantial because latex-fruit reactions can include systemic anaphylaxis, not just mild oral symptoms. Healthcare workers with latex allergy are the highest-risk group for this syndrome.

Yes, eating roasted chestnuts can trigger allergic reactions in sensitized patients through both allergen pathways. Cas s 1 (PR-10) is partially heat-labile but may retain enough allergenicity in roasted chestnuts to cause oral tingling in highly sensitized patients. Cas s 5 (chitinase/hevein) is more heat-stable and may retain allergenic activity after roasting. Patients with confirmed chestnut allergy should discuss chestnut food avoidance with their allergist. Street vendors and food service workers who roast and handle chestnuts daily face combined inhalation and food allergen exposure during the fall harvest season, representing an occupational risk.

Yes, chestnut cross-reacts with birch through the shared PR-10/Bet v 1 protein family. Cas s 1, the major chestnut pollen allergen, is a PR-10 homolog with high structural similarity to Bet v 1 from birch. Both belong to the Fagales botanical order, and the PR-10 cross-reactivity network extends across birch, alder, hazel, hornbeam, oak, beech, and chestnut. Patients sensitized to birch may show positive IgE tests to chestnut pollen even without significant direct chestnut exposure. This cross-reactivity also extends to Rosaceae fruits, hazelnuts, and celery through the same PR-10 pathway.

Yes, screening for chestnut sensitization is clinically recommended for healthcare workers with confirmed latex allergy. The shared hevein domain between latex (Hev b 11) and chestnut (Cas s 5) means cross-reactive IgE may produce unexpected reactions from chestnut pollen inhalation during June-July or from eating chestnuts in fall and winter. Component-resolved testing for Cas s 5 can identify the hevein cross-reactivity pathway specifically. This information guides both seasonal allergy management and dietary counseling. Conversely, patients first identified through chestnut allergy should be tested for latex sensitization to prevent occupational reactions.

Yes, true chestnut (Castanea, Fagaceae) and horse chestnut (Aesculus, Sapindaceae) are completely unrelated trees despite sharing a common name. Castanea is the edible chestnut with well-characterized pollen allergens (Cas s 1, Cas s 5) and documented cross-reactivity networks. Aesculus hippocastanum (horse chestnut) is a common ornamental shade tree with inedible seeds containing aesculin, primarily insect-pollinated, and with no characterized pollen allergens. The chestnut-latex-banana syndrome, PR-10 cross-reactivity, and food allergy concerns all apply exclusively to Castanea chestnuts rather than to horse chestnuts.

Allergen immunotherapy targeting birch or the broader Fagales tree pollen profile may improve oral allergy syndrome mediated by the Cas s 1/PR-10 pathway. Several studies of birch immunotherapy have shown partial improvement in OAS with apples and hazelnuts, though results are variable and not all patients benefit equally. The mechanism involves reducing the IgE pool that cross-reacts between pollen PR-10 proteins and food PR-10 homologs. However, immunotherapy does not address Cas s 5/hevein-mediated reactions (chestnut-latex-banana syndrome), which require separate management through avoidance. A board-certified allergist can set realistic expectations for OAS improvement during immunotherapy.

The American chestnut (Castanea dentata) was historically one of the most important eastern US forest trees, potentially a significant aeroallergen given its Fagaceae family membership and massive pollen production capacity. Chestnut blight (Cryphonectria parasitica) devastated American chestnut populations beginning in the early 1900s, essentially eliminating it as a pollen exposure source. However, active restoration programs using blight-resistant hybrids and transgenic varieties are underway across Appalachian states. As these replanted trees reach reproductive maturity over the coming decades, American chestnut pollen exposure may become a newly relevant clinical consideration for allergists in the region.

Chestnut pollen sensitization rates vary by region and depend heavily on local Castanea planting density. In areas with substantial Chinese chestnut ornamental plantings (mid-Atlantic and Southeast US), sensitization rates among atopic patients are estimated at 3 to 5 percent based on European and cross-reactivity data. In regions without significant chestnut trees, primary sensitization is rare, though cross-reactive IgE from birch or other Fagales pollens may produce positive chestnut tests without direct chestnut exposure. The clinical significance of chestnut allergy is amplified by its dual cross-reactivity profile — even moderate sensitization rates carry disproportionate impact because of the latex-fruit syndrome implications.

Chestnut pollen peaks in June through July across the eastern and central United States. This summer timing is distinctive among major tree pollen allergens — most trees (birch, oak, maple) peak in April through May, while ragweed dominates August through September. The concentrated 2 to 3 week bloom period of Chinese chestnut catkins creates intense local pollen exposure near plantings. The pungent scent of chestnut catkins often alerts patients to the bloom before symptoms begin. If you experience rhinoconjunctivitis symptoms specifically during June-July near identifiable chestnut trees, this seasonal pattern strongly suggests chestnut sensitization rather than grass pollen allergy.

Cooking partially reduces chestnut allergenicity but does not eliminate all risk. Cas s 1 (PR-10) is heat-labile — roasting or boiling chestnuts substantially reduces PR-10 allergenicity, similar to how cooking apples reduces their OAS-triggering potential. Cas s 5 (chitinase/hevein domain) is more heat-stable, meaning roasted chestnuts may retain allergenic activity through this pathway. For patients with Cas s 1-only sensitization, cooked chestnuts may be tolerated, but individual tolerance should be assessed under allergist supervision. For patients with Cas s 5 sensitization, cooked chestnuts still carry risk, and avoidance is generally recommended until tolerance is formally evaluated.